The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
A promising new way to diagnose transthyretin amyloid cardiomyopathy (ATTR-CM or -CA) has the field waiting in anticipation. Early-phase research suggests that the positron emission tomography ...
AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...
Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...
The new understanding of molecular events that drive the various forms of amyloidosis has led to the expansion of therapeutic options to prevent end-stage disease or even offer a cure, which has added ...
AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. The Big ...
Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases. Highlights included presentations from the ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback